April 2022 Content Release Copied

04/28/20222022 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

Additions

Diagnosis

This release contains new staging selections to align with the Revised International Staging System (RISS) adopted for the following problem group:

  • Multiple Myeloma

The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Problems

The following items are available for documentation in Problems and appear on the Charge Capture Report (CCR). Additional ICD-10 codes* may display to present the surrounding nodes.

Problem ICD-10 Code* Choice(s)
Adenocarcinoma of esophagus (disorder)
  • HCC C15.3 – Malignant neoplasm of upper third of esophagus
  • HCC C15.4 – Malignant neoplasm of middle third of esophagus
  • HCC C15.5 – Malignant neoplasm of lower third of esophagus
  • HCC C15.8 – Malignant neoplasm of overlapping sites of esophagus
  • HCC C15.9 – Malignant neoplasm of esophagus, unspecified
  • HCC C16.0 – Malignant neoplasm of cardia
  • D00.1 – Carcinoma in situ of esophagus
Chronic kidney disease (disorder)
  • N18.1 – Chronic kidney disease, stage 1
  • N18.2 – Chronic kidney disease, stage 2 (mild)
  • N18.30 – Chronic kidney disease, stage 3 unspecified
  • N18.31 – Chronic kidney disease, stage 3a
  • N18.32 – Chronic kidney disease, stage 3b
  • N18.4 – Chronic kidney disease, stage 4 (severe)
  • N18.5 – Chronic kidney disease, stage 5
  • N18.6 – End stage renal disease
  • N18.9 – Chronic kidney disease, unspecified
Disorder of Bone (disorder)
  • M94.8X9 – Other specified disorders of cartilage, unspecified sites
  • M94.9 – Disorder of cartilage, unspecified
History of antineoplastic chemotherapy
  • Z92.21 – Personal history of antineoplastic chemotherapy
  • Z92.22 – Personal history of monoclonal drug therapy
History of chemotherapy (situation)
  • Z92.21 – Personal history of antineoplastic chemotherapy
  • Z92.22 – Personal history of monoclonal drug therapy
History of systemic steroid therapy (situation)
  • Z92.240 – Personal history of inhaled steroid therapy
  • Z92.241 – Personal history of systemic steroid therapy
Lymphocytopenia (disorder)
  • B99.8 – Other infectious disease
  • B99.9 – Unspecified infectious disease
  • D72.10 – Eosinophilia, unspecified
  • D72.110 – Idiopathic hypereosinophilic syndrome [IHES]
  • D72.111 – Lymphocytic Variant Hypereosinophilic Syndrome [LHES]
  • D72.118 – Other hypereosinophilic syndrome
  • D72.119 – Hypereosinophilic syndrome [HES], unspecified
  • D72.12 – Drug rash with eosinophilia and systemic symptoms syndrome
  • D72.18 – Eosinophilia in diseases classified elsewhere
  • D72.19 – Other eosinophilia
  • D72.810 – Lymphocytopenia
Malignant tumor of esophagus (disorder)
  • HCC C15.3 – Malignant neoplasm of upper third of esophagus
  • HCC C15.4 – Malignant neoplasm of middle third of esophagus
  • HCC C15.5 – Malignant neoplasm of lower third of esophagus
  • HCC C15.8 – Malignant neoplasm of overlapping sites of esophagus
  • HCC C15.9 – Malignant neoplasm of esophagus, unspecified
  • HCC C16.0 – Malignant neoplasm of cardia
  • D00.1 – Carcinoma in situ of esophagus
Multiple nodules of lung (finding)
  • R91.1 Solitary pulmonary nodule
  • R91.8 Other nonspecific abnormal finding of lung field
Nodule of lung (finding)
  • R91.1 Solitary pulmonary nodule
Personal history of monoclonal drug therapy
  • Z92.21 – Personal history of antineoplastic chemotherapy
  • Z92.22 – Personal history of monoclonal drug therapy
Primary malignant neoplasm of kidney (disorder)
  • C64.1 – Malignant neoplasm of right kidney, except renal pelvis
  • C64.2 – Malignant neoplasm of left kidney, except renal pelvis
  • C64.9 – Malignant neoplasm of unspecified kidney, except renal pelvis
Secondary malignant neoplasm of breast
  • C79.81 Secondary malignant neoplasm of breast
Squamous cell carcinoma of esophagus (disorder)
  • HCC C15.3 – Malignant neoplasm of upper third of esophagus
  • HCC C15.4 – Malignant neoplasm of middle third of esophagus
  • HCC C15.5 – Malignant neoplasm of lower third of esophagus
  • HCC C15.8 – Malignant neoplasm of overlapping sites of esophagus
  • HCC C15.9 – Malignant neoplasm of esophagus, unspecified
  • HCC C16.0 – Malignant neoplasm of cardia
  • D00.1 – Carcinoma in situ of esophagus
Solitary nodule of lung (finding)
  • R91.1 Solitary pulmonary nodule
Vertigo (finding)
  • R42 Dizziness and giddiness

Updates

The Clinical Profile > Problems > Additional Codes service row now contains new selections to accommodate documentation points for Prostate Cancer.

The Clinical Profile > Problems > Additional Details service row no longer contains EGFR Expression documentation for Esophageal Cancer.

Lab Analytes, Panels and Other Services

Additions

  • Anaerobic / aerobic culture panel
  • Calprotectin fecal panel
  • Clonoseq B-cell clonality
  • Clonoseq T-cell clonality
  • Clozapine
  • Clozapine metabolite total
  • Clozapine N Oxide
  • Clozapine panel
  • CMI1146-PD-L1(SP263)
  • Cologuard
  • CT angiography of thorax with contrast
  • eGFR, mL/min/1.73
  • Hepatitis C virus (HCV) Ab with reflex to qualitative NAA panel
  • Hepatitis C virus (HCV) Ab with reflex to quantitative RT-PCR panel
  • Hgb panel
  • HIV-1 RNA quant, Log10copy/mL
  • HLA-A 02:01 panel
  • HLA-A 02:01, A-1
  • HLA-A 02:01, A-2
  • HLA-A 02:01, histocompatibility lab information
  • HLA-A 02:01, reportable comments
  • HLA-A 02:01, test method
  • Immunoglobulin G, subclass 3 panel
  • LDH1, U/L
  • Lupus anticoagulant/cardiolipin Ab panel
  • MTB complex, PCR, respiratory
  • MTB complex, specimen source
  • Myelin basic protein, serum, ng/mL
  • Myelin oligodendrocyte glycoprotein (MOG- IgG1) ab, CBA panel
  • Norclozapine
  • Oligoclonal bands, serum
  • PD-L1(SP263)
  • Phosphatidylinositol, IgA, APL/units
  • Phosphatidylinositol, IgG, GPL/units
  • Phosphatidylinositol, IgM, MPL/units
  • SARS-CoV-2 spike Ab dilution, U/mL
  • Tempus Heme panel
  • Viral culture, respiratory, rapid

Imaging

  • CT angiography of thorax with contrast
  • Doppler ultrasound
  • VQ – Ventilation perfusion scan

Medications

Additions

  • Etopophos (Etopophos IV)
  • Etopophos Intraventricular
  • Etopophos IV
  • Lanraplenib invest Oral
  • Lutetium Lu-177 Vipivotide Tetraxetan IV 27 mCi/mL (1,000 MBq/mL)
  • LY2523355 invest IV
  • MK-7684A invest IV
  • Nivolumab-Relatlimab-rmbw IV 240 mg-80 mg/20 mL
  • NP Thyroid (Thyroid (Pork) Oral)
  • NP-G2-044 invest Oral
  • Oleclumab invest (MEDI9447 invest IV)
  • Opdualag (Nivolumab-Relatlimab-rmbw IV 240 mg-80 mg/20 mL)
  • Pluvicto (Lutetium Lu-177 Vipivotide Tetraxetan IV 27 mCi/mL (1,000 MBq/mL)
  • Provayblue (Methylene Blue IV)
  • Sodium Chloride Solution Non-Oral 9 % Etopophos (Etopophos Intraventricular)
  • ST101 invest IV      TOL2506 invest Subcutaneous

Updates

Medication Update
Alpelisib Oral New Sig: 0 mg orally daily; A 14-day supply of 28 tablets (14 tablets, 200 mg alpelisib per tablet and 14 tablets; 50 mg alpelisib per tablet); quantity sufficient for 14 days.
Bevacizumab IV New default Sig: 5 mg/kg intravenously Piggyback once.

New Instructions: Dilute with NS to a total volume of 100 mL. First infusion over 90 minutes. If first infusion is tolerated, administer second infusion over 60 minutes. If second infusion is tolerated, subsequent infusions may be administered over 30 minutes.                                                                                        Do not mix or administer with dextrose solution. NOTE: This is Avastin.
Bevacizumab-bvzr IV New default Sig: 5 mg/kg intravenously Piggyback once.

New Instructions: Dilute with NS to a total volume of 100 mL. First infusion over 90 minutes. If first infusion is tolerated, administer second infusion over 60 minutes. If second infusion is tolerated, subsequent infusions may be administered over 30 minutes. Do not mix or administer with dextrose solution. NOTE: This is Zirabev.
Bevacizumab-awwb IV New default Sig: 5 mg/kg intravenously Piggyback once.

New Instructions: Dilute with NS to a total volume of 100 mL. First infusion over 90 minutes. If first infusion is tolerated, administer second infusion over 60 minutes. If second infusion is tolerated, subsequent infusions may be administered over 30 minutes. Do not mix or administer with dextrose solution. NOTE: This is Mvasi.
Everolimus Oral (Afinitor) New Instructions: Take whole with water, with or without food.
Letrozole Oral New default Form & Unit: 2.5 mg tablet
Loncastuximab tesirine invest IV New Form: 10 mg lyophilized powder
Sargramostim Subcutaneous New Sig: 250 mg subcutaneously once
Sargramostim IV New Sig: 250 mg intravenously once
T3011 1x10e8 pfu invest IV New Unit: X 10e8
T3011 1x10e7 pfu invest IV New Unit: X 10e7

Regimens

This section does not include clinical trial regimens.

Additions

Regimen Name Diagnosis
Bevacizumab (5 mg/kg) BIOSIMILAR Q14D (Colon, Rectal) (Addition to Chemotherapy) Colon Cancer, Rectal Cancer
Bortezomib + Dexamethasone + Rituximab IV BIOSIMILAR (BDR) (Part 2 of 2) Waldenstrom’s Macroglobulinemia
Cladribine D1-5 fb Rituximab IV BIOSIMILAR D1,8,15,22 Q28D Leukemia, Hairy Cell
Folfirinox (Modified) Q14D (3 mo) Rectal Cancer; Pancreatic Cancer
Folfirinox Q14D (3 mo) Rectal Cancer; Pancreatic Cancer
Gemcitabine D1,8 + Abraxane D1,8 + Cisplatin D1,8 Q21D Pancreatic Cancer
Irinotecan + Bevacizumab BIOSIMILAR Q14D
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) Q42D
Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D (Neoadjuvant NSCLC) Lung Cancer, Non-Small Cell (NSCLC)
Nivolumab + Paclitaxel + Carboplatin Q21D (Neoadjuvant NSCLC) Lung Cancer, Non-Small Cell (NSCLC)
Nivolumab + Pemetrexed + Cisplatin Q21D (Neoadjuvant NSCLC) Lung Cancer, Non-Small Cell (NSCLC)
Nivolumab and Relatlimab-rmbw (Opdualag) Q28D Brain Tumor (Parent)
Pacritinib Q30D Myelofibrosis; Polycythemia Vera; Myeloproliferative Disorder

Updates

To complete the initiative to update regimens impacted by the new version 2017071 of the NCPDP SCRIPT standard, the following premedications have been updated with an active Unit of Measure (UOM):

  • Aprepitant Oral
  • Rolapitant Oral
  • Netupitant-Palonosetron Oral

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • Bile Duct Cancer (Parent)
  • Fallopian Tube Cancer
  • Gestational Trophoblastic Tumor
  • Leukemia, Acute Lymphocytic (ALL)
  • Leukemia, Acute Myeloid (AML)
  • Leukemia, Chronic Lymphocytic (CLL)
  • Leukemia, Chronic Myeloid (CML)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Merkel Cell Carcinoma
  • Gallbladder Cancer
  • Gastric Cancer
  • Neuroendocrine Tumor, Carcinoid (Parent)
  • Ovarian and Primary Peritoneal Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Renal Cell Carcinoma (RCC)
  • Sarcoma, Bone (Parent)
  • Sarcoma, Soft Tissue (Parent)
  • Testicular Cancer (Parent)
  • Thymoma, Malignant
  • Uterine Cancer (Parent

Removals

  • Bortezomib D1,4,8,11 + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone D1-5 (VR- CAP) Q21D
  • Capecitabine D1-14 Q21D (Part 1 of 3: Capecitabine pre-XRT, Rectal Cancer)
  • Capecitabine + XRT Q38D (Part 2 of 3: Capecitabine + XRT, Rectal Cancer)
  • Capecitabine D1-14 Q21D (Part 3 of 3: Capecitabine post-XRT, Rectal Cancer)
  • Carboplatin Q28D (G1)/ Carboplatin D1 Q28D (Uterine) (G2)
  • Paclitaxel D1,8,15 + Bevacizumab D1,15 Q28D (Breast)
  • Rituximab IV +/- Modified Hyper CVAD Q21D (Part 1 of 2: Hyper CVAD/HD Methotrexate + Cytarabine)
  • Rituximab IV +/- Modified Hyper CVAD Q28D (Part 2 of 2: Methotrexate + Pegaspargase Intensification)

Renames

Previous Name New Name
Acalabrutinib Acalabrutinib Q30D
Capecitabine + XRT Q25D Capecitabine + XRT Q35D (Rectal, Bile Duct)
Carboplatin D1 Q21D Carboplatin Q21D

Research

Additions

To support data migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMedSM EHR to iKnowMedSM Generation 2.

Updates

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instructions Other Changes
USOR 17087 X X
USOR 18020 X X No longer available for ordering:

USOR 18020 Part 2 Nivolumab + Ipilimumab + BMS-986253 or Placebo Q21D
USOR 18095 X
USOR 18261 X X
USOR 18283 X
USOR 19044 X X X Now available for ordering:

USOR 19044 Osimertinib (PO; Daily)
USOR 19062 X X No longer available for ordering:

USOR 19062 Safety Run-In Tazemetostat BID + Lenalidomide D1-21 + Rituximab IV Q28D
USOR 19088 X X X
USOR 20175 X X X
USOR 20177 X X
USOR 20186 X X
USOR 20223 X
USOR 20260 X X X
USOR 20307 X X X
USOR 20309 X X X
USOR 20310 X X X
USOR 20331 X
USOR 20346 X X X
USOR 20361 X X
USOR 20382 X X X
USOR 20384 X X X No longer available for ordering:

USOR 20384 AMG 510 (PO; Daily) + Paclitaxel + Carboplatin Q21D

Now available for ordering:

  • USOR 20384 Part 2 Cohort D AMG 510 (PO; Daily) + Pemetrexed + Carboplatin Q21D
  • USOR 20384 Part 2 Cohort D Pemetrexed + Pembrolizumab Maintenance 21D
USOR 20386 X X X
USOR 20388 X X X
USOR 20402 X
USOR 21194 X X X
USOR 21207 X X
USOR 21270 X X X
USOR 21271 X X X
USOR 21304 X X
USOR 21308 X X
USOR 21321 X
USOR 21400 X X
USOR 21527 X

Billing & HCPCS Codes

Updates

Medication HCPCS Code(s)
Cabenuva (Cabotegravir-Rilpivirine IM ER Susp 200mg/mL-300 mg/mL) J0741 per:

4 mL

6 mL
Medication HCPCS Code(s)
Cabotegravir IM SR Susp J0741 per:

2 mg
Delestrogen (EstradioL Valerate Subcutaneous) J1380 per:

10 mg
Hepatitis B Virus Vaccine Recomb, isoform S,M,L (PF) IM (brand: Prehevbrio (PF) IM) 90759 per:

10 mcg

1 mL
Difelikefalin IV J0879 per:

0.1 mcg
Kimmtrak (Tebentafusp-tebn IV) J3590 per:

100 mcg
Lutetium Lu-177 Vipivotide Tetraxetan IV 27 mCi/mL (1,000 MBq/mL) A9699 per:

7.4 mL
Pfizer (COVID-19 Vac, Tris (Pfizer) (PF) IM (6 months thru 4 yrs) (Unapproved)) 91308 per:

3 mcg

0.2 mL
Pluvicto (Lutetium Lu-177 Vipivotide Tetraxetan IV 27 mCi/mL (1,000 MBq/mL) A9699 per:

200 mCi

7.4 GBq
Pylarify (Piflufolastat F 18 IV) A9595 per:

1 mCi

37 MBq
Rilpivirine IM J0741 per:

3 mg